BAJAJ BROKING
Sun Pharmaceutical Industries has announced its financial results for the third quarter of the fiscal year 2024-2025, showcasing significant growth in both revenue and net profit. The company's consolidated revenue from operations reached ₹13675.46 crore, marking a notable increase from ₹12380.70 crore in the same quarter of the previous year. Net profit after tax also saw a substantial rise, amounting to ₹2912.98 crore compared to ₹2560.54 crore in the corresponding quarter last year.
Revenue Growth: The company achieved a 10.5% year-over-year increase in revenue from operations, rising from ₹12380.70 crore in Q3 FY23-24 to ₹13675.46 crore in Q3 FY24-25.
Net Profit Increase: Net profit after tax grew by 13.8%, reaching ₹2912.98 crore in the current quarter, up from ₹2560.54 crore in the same period last year.
Total Income: Total income for the quarter stood at ₹14141.08 crore, compared to ₹12630.90 crore in Q3 FY23-24.
Total Expenses: The company's total expenses were ₹10348.51 crore, up from ₹9560.74 crore in the previous year's corresponding quarter.
In the third quarter of FY24-25, Sun Pharmaceutical Industries reported a consolidated revenue from operations of ₹13675.46 crore, reflecting a 10.5% increase from ₹12380.70 crore in Q3 FY23-24. Other income also saw a significant rise, totaling ₹4,65.62 crore, up from ₹250.20 crore in the same quarter last year. Consequently, the total income reached ₹14141.08 crore, compared to ₹12630.90 crore in the previous year's corresponding quarter.
The company's total expenses increased to ₹10348.51 crore from ₹9560.74 crore in Q3 FY23-24. Despite the rise in expenses, profit before tax (PBT) grew to ₹3476.40 crore, up from ₹3000.35 crore in the same period last year. After accounting for a tax expense of ₹558.86 crore, net profit after tax (PAT) stood at ₹2912.98 crore, a 13.8% increase from ₹2560.54 crore in Q3 FY23-24.
India Formulations:
Sales: ₹4,300.4 crore, up 13.8% year-over-year.
Contribution: Approximately 32% of total consolidated sales.
Nine-month Sales: ₹12,710.0 crore, a 13.7% increase over the same period last year.
Market Share: Increased from 7.8% to 8.2% in the ₹2,21,400 crore Indian pharmaceutical market (AIOCD AWACS MAT Dec-2024).
Prescription Rankings: Ranked No.1 by prescriptions in 12 doctor categories (SMSRC, July-Oct 2024).
New Products: Launched 12 new products in Q3FY25.
US Formulations:
Sales: US$474 million, a slight decline of 0.7% from the previous year.
Contribution: Approximately 30% of total consolidated sales.
Nine-month Sales: US$1,457 million, a 5.7% growth over the same period last year.
Emerging Markets (EM) Formulations:
Sales: US$277 million, a 10.1% increase year-over-year.
Contribution: Approximately 17% of total consolidated sales.
Nine-month Sales: US$854 million, up 7.2% over the same period last year.
Rest of World (ROW) Formulations:
Sales: US$259 million, a significant growth of 21.0% compared to the previous year.
Contribution: Approximately 16% of total consolidated sales.
Nine-month Sales: US$647 million, a 5.2% increase over the same period last year.
Active Pharmaceutical Ingredients (API):
External Sales: ₹567.8 crore, a 21.8% rise year-over-year.
Nine-month Sales: ₹1,596.2 crore, growing by 6.2% over the same period last year.
Research & Development (R&D):
Investment: ₹845.0 crore in Q3FY25, accounting for 6.3% of sales, compared to ₹824.5 crore in Q3FY24.
Nine-month R&D Expense: ₹2,431.9 crore, representing 6.2% of sales.
Sector expectations for Sun Pharmaceutical Industries Q3 Results FY24-25
The pharmaceutical sector anticipated robust performance from Sun Pharmaceutical Industries in Q3 FY24-25, given the company's strategic initiatives and expanding specialty product portfolio. The reported results, with significant increases in both revenue and net profit, align with these expectations and underscore the company's strong position in the industry.
Management Commentary
Dilip Shanghvi, Chairman and Managing Director of the Company said, “Our performance in the quarter showed all-round improvement. Product sales in Global Specialty crossed 1/5th of overall sales. Our market share gain in India has been driven by industry leading volume growth. Emerging Markets demonstrated strong performance in spite of currency challenges across geographies. All our businesses remain well positioned for future.”
This information is sourced from BSE.
Particulars | 31-12-2024 (₹ million) | 31-12-2023 (₹ million) |
Revenue from Operations | 136,754.6 | 123,807.0 |
Other Income | 4,656.2 | 2,502.0 |
Total Income | 141,410.8 | 126,309.0 |
Total Expenses | 103,485.1 | 95,607.4 |
Profit Before Tax (PBT) | 34,764.0 | 30,003.5 |
Tax Expense (Net) | 5,588.6 | 4,323.2 |
Net Profit After Tax (PAT) | 29,129.8 | 25,605.4 |
Note: All financial figures are sourced from Sun Pharmaceutical Industries’s official quarterly earnings report.
The financial data for Sun Pharmaceutical Industries Q3 FY24-25 results is sourced from BSE.
Sun Pharmaceutical Industries is scheduled to announce its Q3 FY24-25 earnings on January 31, 2025. Analysts anticipate steady double-digit growth in both the Indian and U.S. markets, contributing to a mid-teen increase in net profit. According to a Moneycontrol poll of 10 brokerages, the company's net profit is projected to rise by 15% to ₹2,893 crore, up from ₹2,524 crore in the same quarter of the previous fiscal year. Revenue is expected to increase by 10% to ₹13,375 crore, compared to ₹12,157 crore in the prior year. However, operational performance may experience a slight decline due to a reduced contribution from the cancer drug Revlimid. EBITDA margins are forecasted to decrease by 20 basis points year-over-year to 27.9% in Q3.
Revenue Growth: Estimated 10% year-over-year increase to ₹13,375 crore.
Net Profit: Projected 15% rise to ₹2,893 crore.
EBITDA Margin: Expected to decline by 20 basis points to 27.9%.
India Business: Continued double-digit growth anticipated.
U.S. Business: Sustained double-digit growth expected.
Revlimid Contribution: Anticipated decrease impacting operational performance.
In the upcoming Q3 FY24-25 results, Sun Pharma is expected to report a 10% increase in revenue, reaching ₹13,375 crore, driven by robust performance in both domestic and international markets. The net profit is projected to grow by 15% to ₹2,893 crore, reflecting strong operational efficiency. Despite these positive trends, the EBITDA margin is anticipated to experience a slight decline of 20 basis points, settling at 27.9%, primarily due to a lower contribution from Revlimid.
Note: These figures are based on analyst estimates and are subject to change upon the official release of Sun Pharmaceutical Industries's financial results.
The financial data estimates for Sun Pharmaceutical Industries Q3 FY24-25 results are sourced from Money Control.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
ONGC Q3 Results FY24-25 Highlights
31 Jan, 2025 | 4 Min. read
Stock Market Live Updates
31 Jan, 2025 | 25 Min. read
IndusInd Bank Q3 Results FY24-25 Highlights
31 Jan, 2025 | 3 Min. read
Sun Pharmaceutical Industries Q3 Results FY24-25
31 Jan, 2025 | 6 Min. read
Nestle India Q3 Results FY24-25
31 Jan, 2025 | 4 Min. read
L&T Q3 FY25 Results
30 Jan, 2025 | 5 Min. read
Bajaj Finserv Q3 FY25 Results
30 Jan, 2025 | 3 Min. read
Stock Market Live Updates | 30 Jan 2025
30 Jan, 2025 | 9 Min. read
BEL Q3 Results FY24-25
30 Jan, 2025 | 3 Min. read
Dabur Q3 FY25 Results
30 Jan, 2025 | 3 Min. read
Bank of Baroda Q3 FY25 Results
29 Jan, 2025 | 4 Min. read
Maruti Suzuki India Q3 Results FY24-25: Revenue Increases by 15.7%
29 Jan, 2025 | 4 Min. read
Analysis to Become a Pro Investor
28 Dec, 2023 | 4 Min. read
Women In Real Estate Investing (Investree)
28 Dec, 2023 | 5 Min. read
How To Check Prudent Corporate Advisory IPO Allotment Status
27 Dec, 2023 | 3 Min. read
How To Boost Credit Score? – Steps to Improve Creditworthiness
27 Dec, 2023 | 4 Min. read
Advantages and Disadvantages of Opening Multiple Demat Accounts
26 Dec, 2023 | 4 Min. read
7th CPC LTC: Leave Travel Concession Rules for Central Government Employees
26 Dec, 2023 | 4 Min. read
7th Pay Commission: House Building Advance (HBA) Interest Rate FY 2023-24
26 Dec, 2023 | 5 Min. read
The Future of Trading: Exploring Bajaj Broking’s Demat Features
26 Dec, 2023 | 6 Min. read
7th Central Pay Commission Cpc Fitment Table
23 Dec, 2023 | 7 Min. read
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading